Boston Scientific management check
BSX · Health Care · Health Care Equipment · CEO Michael F. Mahoney
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2021
100100thDetail
$100 invested at the start of fiscal 2021 grew to $265, against $148 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8454thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.68 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.8% of net income
What does the CEO cost owners?
$23.5m pay · $2.9bn net income, FY2025
5758thDetail
$23.5m of reported pay in fiscal 2025, against $2.9bn of net income.
- GoodInsiders are buying
Do they own the stock?
252,241 shares
6 mo: ▲ $9.5m bought · ▼ $0 sold
8095thDetail
4 insiders bought $9.5m on the open market in the last six months, with their own money, near the lows.
- WatchShare count growing
Are owners being diluted?
Diluted shares +1.1% a year; flagged above +2%
Stock pay 1.5% of revenue
3719thDetail
Diluted shares changed +1.1% a year over the last three fiscal years. Stock-based pay was 1.5% of revenue in the latest year.
- Flag15 leadership filings in 3 years
Is leadership stable?
15 filings under 8-K 5.02 in 3 years
CEO: Michael F. Mahoney
5025thDetail
CEO in the pay table: Michael F. Mahoney. 15 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- WatchAn annual report was amended
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 110-K amended
7015thDetail
No restatements, auditor changes or late filings since 2021. 1 amended annual report.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 18, 2026.
Pay tied most to Adjusted Net Sales
Other key measuresAdjusted Net Sales*Adjusted EPS*Adjusted OIM*Organic Net Sales Growth*Relative Total Shareholder Return
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Michael F. Mahoney | $23.5m | $33.0m | $5.8m | $265 | $148 | $2.9bn |
| 2024 | Michael F. Mahoney | $21.4m | $65.8m | $5.5m | $248 | $129 | $1.8bn |
| 2023 | Michael F. Mahoney | $18.7m | $38.6m | $4.9m | $161 | $126 | $1.6bn |
| 2022 | Michael F. Mahoney | $16.9m | $21.6m | $4.9m | $129 | $124 | $698.0m |
| 2021 | Michael F. Mahoney | $16.1m | $20.4m | $3.9m | $118 | $126 | $1.0bn |
Insiders and the CEO's stake
- Chairman, President & CEO
- Michael F Mahoney
- Shares held
- 252,241
- Latest Form 4
- Nov 4, 2026
4 insiders bought $9.5m on the open market in the last six months, with their own money, near the lows.
Open-market trades by officers and directors since May 21, 2026.
- BoughtMichael F MahoneyChairman, President & CEO$9.0mAug 3, 2026
- BoughtEdward J LudwigDirector$227kJul 31, 2026
- BoughtDavid C HabigerDirector$157kAug 5, 2026
- BoughtSusan E MoranoDirector$100kAug 25, 2026
Leadership and governance on file
All 22 filings
- Nov 17, 2026Leadership change8-K 5.02
- Oct 7, 2026Leadership change8-K 5.02
- Sep 23, 2026Leadership change8-K 5.02
- Feb 23, 2026Leadership change8-K 5.02
- Feb 5, 2026Leadership change8-K 5.02
- Nov 19, 2025Leadership change8-K 5.02
- Oct 23, 2025Leadership change8-K 5.02
- Sep 4, 2025Leadership change8-K 5.02
- Apr 23, 2025Leadership change8-K 5.02
- Feb 12, 2025Leadership change8-K 5.02
- Nov 22, 2024Leadership change8-K 5.02
- Jul 30, 2024Leadership change8-K 5.02
- May 10, 2024Leadership change8-K 5.02
- Feb 21, 2024Annual report amended10-K/A
- Jan 31, 2024Leadership change8-K 5.02
- Nov 22, 2023Leadership change8-K 5.02
- Jun 27, 2023Leadership change8-K 5.02
- Jan 31, 2023Leadership change8-K 5.02
- Nov 21, 2022Leadership change8-K 5.02
- May 6, 2022Leadership change8-K 5.02
- Apr 5, 2022Leadership change8-K 5.02
- Nov 23, 2021Leadership change8-K 5.02
Latest shareholder vote results: May 5, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $138.0m returned to owners in buybacks and dividends, and $1.2bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $11.9bn | $12.7bn | $14.2bn | $16.7bn | $20.1bn |
| Net income | — | — | — | — | — |
| Stock-based pay | $194.0m | $220.0m | $233.0m | $266.0m | $299.0m |
| Buybacks | $0 | $0 | — | — | — |
| Dividends | $55.0m | $55.0m | $28.0m | $0 | — |
| Diluted shares | 1434m | 1440m | 1464m | 1486m | 1495m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.